New Targets for the Treatment of Hypertension and Associated Diseases

1st Edition, Volume 94 - June 2, 2022
Imprint: Academic Press
Editors: William B. Campbell, John D. Imig
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 1 0 8 7 - 3
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 1 0 8 8 - 0

New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volu… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

Cover image
Title page
Table of Contents
Copyright
Contributors
Chapter One: The CYP/20-HETE/GPR75 axis in hypertension
Abstract
1: Introduction
2: 20-HETE biosynthesis, regulation, and metabolism
3: Human CYP polymorphisms associated with hypertension
4: The 20-HETE receptors
5: 20-HETE and the kidney in hypertension
6: 20-HETE, vascular smooth muscle cells (VSMCs) and hypertension
7: 20-HETE, endothelial cell dysfunction and activation
8: 20-HETE and the renin angiotensin system (RAS)
9: 20-HETE and vascular remodeling
10: 20-HETE and cardio-metabolic disease
11: 20-HETE synthesis inhibitors and 20-HETE receptor blockers (20HRBs)
12: Conclusion
References
Chapter Two: Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury
Abstract
1: Introduction
2: CYP Epoxygenase, sEH, and EET regulation in human hypertension
3: EET contribution to experimental hypertension and kidney disease
4: Therapeutic development of EET mimics/analogs
5: EET analogs in preclinical hypertension and kidney disease
6: Advances toward clinical trials
7: Conclusion
References
Further reading
Chapter Three: Pharmacological developments in antihypertensive treatment through nitric oxide—cGMP modulation
Abstract
1: Introduction
2: Strategies to improve eNOS activity
3: (Re)Activation of sGC
4: PKG activation as a drug target
5: PDE inhibitors
6: Interventions targeted at reduction of ROS
7: Conclusion
References
Chapter Four: Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications
Abstract
1: Introduction
2: S1P synthesis, kinetics and general function
3: Receptor-mediated S1P signaling
4: S1P function at the endothelium
5: S1P at vascular level
6: S1P effects at the kidney
7: The hazy link between the immune system and hypertension and the role of S1P
8: A role for S1P also in pulmonary arterial hypertension
9: Indirect effects of S1P on cardiovascular events that may impact the control of blood pressure
10: Conclusion
References
Chapter Five: Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease
Abstract
1: Introduction
2: Warfarin as a test case
3: Polymorphisms within receptors for antihypertensive drugs
4: Future directions to functionalize personalized medicine
5: Conclusion
References
Chapter Six: Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension
Abstract
1: Introduction
2: Relaxin/serelaxin in hypertension and vascular cells
3: Relaxin/serelaxin in the context of heart failure
4: Future directions
5: Conclusion
References
Chapter Seven: Cardiovascular effects of GLP-1 receptor agonism
Abstract
1: Introduction
2: Overview of GLP-1
3: GLP-1 peptide agonists for use in type 2 diabetes
4: Cardiovascular protection by GLP-1RA therapy in clinical trials
5: Putative mechanisms underlying cardioprotection
6: Biased agonism and GLP-1RA action: Future directions
7: Conclusion
References
Chapter Eight: ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease
Abstract
1: Introduction
2: ADAMs and ADAMTS structure
3: Sources and tissue distribution of ADAM and ADAMTS family
4: ADAMs and ADAMTS activation
5: ADAMs targets, substrates, functions and mouse KO phenotype
6: ADAMTS targets, substrates, functions and mouse KO phenotype
7: ADAMs and ADAMTS inhibitors
8: ADAMs and ADAMTS in vascular processes and malfunction
9: ADAMs and ADAMTS in cardiovascular disease
10: Conclusion
References
Chapter Nine: Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
Abstract
1: Introduction
2: Diastolic versus systolic dysfunction
3: Anthracyclines and the mechanisms of diastolic dysfunction
4: Anthracyclines and pathophysiologic trajectories of diastolic dysfunction
5: General considerations on anthracycline cardiotoxicity prevention
6: Pharmacologic interventions on cancer treatment-related diastolic dysfunction: Lessons from natriuretic peptide
7: Novel potential pharmacologic opportunities
8: Conclusion
Conflict of interest statement
References

William B. Campbell

William B. Campbell, PhD, Professor and Chairman of the Department of Pharmacology and Toxicology at the Medical College of Wisconsin received his PhD from the University of Texas Health Science Center in Dallas. After post-doctoral work and another year as an instructor at the Medical College of Wisconsin he moved to the Department of Pharmacology at the University of Texas Southwestern Medical Center where he would eventually become full Professor of Pharmacology. In 1992 he became Chair of Pharmacology at the Medical College of Wisconsin. For the past 30 years, Dr. Campbell has been investigating the contribution of various vasoactive agents that regulate blood pressure. His studies on endothelium-derived factors that regulate blood pressure and vascular tone identified the major vasoactive metabolites of arachidonic acid that are produced by the vascular endothelium. He has consistently made major contributions in research, teaching and service to various institutions and to the scientific community in general. Dr. Campbell has received numerous awards for his research including the Research Career Development Award from the National Institutes of Health. In 2006, he received the Novartis Award for Hypertension Research, the most prestigious award in the world in the area of hypertension research. He has received the Outstanding Mentor and Teaching Award from the Medical College of Wisconsin.

Affiliations and expertise

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, USA

John D. Imig

John D. Imig, Ph.D. is a Professor and Director Drug Discovery at the Medical College of Wisconsin. Dr. Imig has received a number of awards for his research in cardiovascular and renal physiology included the prestigious Established Investigator Award from the American Heart Association. Dr. Imig has authored over 200 publications related to the antihypertensive properties and renal and cardiovascular protective properties of angiotensin receptor antagonists and soluble epoxide hydrolase inhibitors.

Affiliations and expertise

Drug Discovery Center, Medical College of Wisconsin, Milwaukee, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health